首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CXCL10 |
| Uniprot No | P02778 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-98aa |
| 氨基酸序列 | VPLSRTVRCT CISISNQPVN PRSLEKLEII PASQFCPRVE IIATMKKKGE KRCLNPESKA IKNLLKAVSK ERSKRSP |
| 预测分子量 | 9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CXCL10重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*Cloning and Functional Characterization of CXCL10/IP-10: A Key Chemokine in Antiviral Immunity*
**作者**：Luster, A.D. et al.
**摘要**：该研究首次克隆并表达了重组CXCL10蛋白，证明其在招募Th1型淋巴细胞和抗病毒免疫中的关键作用，揭示了CXCL10与干扰素-γ的协同效应。
2. **文献名称**：*CXCL10 Expression in Tumor Microenvironment Promotes T Cell Exclusion and Resistance to Immunotherapy*
**作者**：Liu, C. et al.
**摘要**：通过重组CXCL10蛋白实验，研究发现高表达CXCL10的肿瘤微环境会排斥细胞毒性T细胞，导致免疫治疗抵抗，提示其作为癌症治疗靶点的潜力。
3. **文献名称**：*Recombinant CXCL10 as a Biomarker for Autoimmune Disease Progression*
**作者**：Antonelli, G. et al.
**摘要**：利用重组CXCL10蛋白检测患者血清水平，发现其浓度与类风湿性关节炎和系统性红斑狼疮的疾病活动度显著相关，支持其作为临床生物标志物的应用。
---
**备注**：以上文献为示例，实际引用需根据具体研究方向补充完整信息(期刊、年份、DOI等)。建议通过PubMed或Web of Science以“CXCL10 recombinant protein”为关键词检索最新研究。
**Background of CXCL10 Recombinant Protein**
CXCL10 (C-X-C motif chemokine ligand 10), also known as interferon gamma-induced protein 10 (IP-10), is a small cytokine belonging to the CXC chemokine family. It is primarily produced by monocytes, endothelial cells, and fibroblasts in response to proinflammatory stimuli, particularly interferon-gamma (IFN-γ). CXCL10 functions by binding to its cognate receptor, CXCR3. which is highly expressed on activated T cells (especially Th1 cells), natural killer (NK) cells, and dendritic cells. This interaction plays a critical role in recruiting immune cells to sites of inflammation, infection, or tissue injury, thereby modulating adaptive and innate immune responses.
Recombinant CXCL10 protein is engineered using expression systems such as *E. coli* or mammalian cells, ensuring high purity and bioactivity for research applications. It typically exists as a non-glycosylated monomeric protein with a molecular weight of ~8-10 kDa. The recombinant form retains the native protein's ability to induce chemotaxis, regulate cell proliferation, and participate in immune signaling pathways.
CXCL10 is implicated in various pathological and physiological processes, including viral infections (e.g., hepatitis, COVID-19), autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis), and cancer. In cancer biology, CXCL10 exhibits dual roles: it can promote anti-tumor immunity by recruiting effector T cells, but it may also support tumor progression through angiogenesis or immunosuppressive microenvironment formation.
Researchers utilize recombinant CXCL10 to study its role in disease models, screen therapeutic agents, or explore diagnostic biomarkers. Its therapeutic potential is being investigated in contexts such as immunotherapies, anti-angiogenic treatments, and as a prognostic indicator for inflammatory conditions.
Overall, CXCL10 recombinant protein serves as a vital tool for dissecting immune mechanisms and developing targeted therapies.
×
